"This is a good speculative stock." said Cramer about the clinical contract research company providing late phase clinical development services to the biotechnology, pharmaceutical and the medical device industries.
More from Investing
The strength in the Russell 2000 is a positive sign for stock-picking.
Amid the Fed's shift in tone and the market's reaction, I'm eyeing Apex Technology Acquisition.
Here's what Jim Cramer has to say about the stock.
While the Fed hasn't made any actual rate policy changes, seven Fed members are now predicting a hike in 2022 vs. four previously.